Cytomegalovirus (CMV) infection is an important cause of morbidity and mortality after allogeneic transplant. Interstitial pneumonia (IP) is the most common manifestation of CMV in BMT patients, with a 30-48% mortality rate despite adequate treatment. Most CMV infection occurs in the first 100 days. However, prolonged ganciclovir (GCV) prophylaxis has favored the occurrence of late CMV IP, probably by inhibition of the development of CMV-specific T cell lymphocyte responses. We report the case of a patient treated with an allogeneic BMT who received pre-emptive GCV until day +100 because of CMV-positive antigenemia. He developed a CMV IP on day +811 post BMT, which responded to treatment. We intend to alert clinicians that even at long-term (Ͼ1 year) post-BMT, CMV is a possible cause of IP in high-risk patients. Bone Marrow Transplantation (2000) 26, 443-444. Keywords: CMV infection; very late interstitial pneumonia; allogeneic BMT Despite the recent advances in diagnosis, prophylaxis and treatment, cytomegalovirus (CMV) infection is still an important cause of morbidity and mortality after allogeneic blood and marrow transplantation. The major risk factor is pre-transplant seropositivity of the patient. Secondary factors include donor seropositivity, severe graft-versus-host disease (GVHD), unrelated or mismatched transplants, and delayed recovery of the CMV-specific cytotoxic T cell response.
Despite the recent advances in diagnosis, prophylaxis and treatment, cytomegalovirus (CMV) infection is still an important cause of morbidity and mortality after allogeneic blood and marrow transplantation. The major risk factor is pre-transplant seropositivity of the patient. Secondary factors include donor seropositivity, severe graft-versus-host disease (GVHD), unrelated or mismatched transplants, and delayed recovery of the CMV-specific cytotoxic T cell response. 1 Interstitial pneumonia remains the most common manifestation of CMV in BMT patients, with an incidence of ෂ15% and an 85% mortality if untreated. The combination of ganciclovir (GCV) plus immune globulin has reduced the mortality to 30-48%. 2 Most CMV infections occur in the early post-engraftment period (the first 100 days) but prophylactic measures during this period has allowed development of the infection later in the transplant course. 3 We report a case of very late CMV pneumonia (CMVP) after allogeneic BMT (Ͼ1 year post transplant).
Case report
A 44-year-old male received an allogeneic BMT for treatment of myelodysplastic syndrome. Conditioning was busulphan and cyclophosphamide, while GVHD prophylaxis was cyclosporin and methotrexate. He was considered at 'high-risk' of CMV disease (patient and donor CMV seropositive before the transplant). CMV prophylaxis included acyclovir (500 mg/m 2 three daily i.v.) from day Ϫ1 to day +26. Pre-emptive therapy with GCV was started on day +27 because of CMV screening test positivity (antigenemia). The dose was 5 mg/kg twice daily i.v. for 2 weeks, then 5 mg/kg day i.v. for 5 days a week maintained until day +100. Antigenemia assessment carried out on day +104 was negative. A diagnosis of acute GVHD was made on day +35, and corticosteroid therapy was given. Unfortunately, he developed extensive chronic GVHD, with skin, mucosal and lung involvement (bronchiolitis). Variable doses of corticosteroids and cyclosporin had been given in an attempt to control GVHD, and he developed various bacterial respiratory infections during this period. On day +784, thalidomide was started in an effort to reduce the dose of steroids. On day +805 the patient developed low-grade fever and cough, with no improvement after 5 days of oral antibiotics. On day +811 he was admitted because of worsening dyspnea, hypoxemia (PaO 2 of 49 mm Hg and oxygen saturation of 87%) and bilateral basal interstitial lung infiltrates on a chest X-ray. A bronchoalveolar lavage (BAL) was done, the fluid tested for CMV, HSV, Pneumocystis carinii, fungi and bacteria, and the results were negative. CMV detection in alveolar cells was performed using a mouse anti-cytomegalovirus (blend) monoclonal antibody. IgG dosage was 7681 mg/dl (normal range 800-1700 mg/dl), IgG and IgM were in the normal ranges, CD4 and CD8 counts revealed 275 cells/l and 285 cells/l, respectively, and an ELISA test for HIV was negative on admission. CMV viremia was confirmed through CMV antigenemia testing (12 positive cells in 200 000 cells tested). GCV and intravenous immune globulin were started on day +812. CMV antigenemia was still tested present (21 stained cells in 200 000 cells) on day +817. However, the patient became afebrile and progressive improvement on respiratory function was observed (PaO 2 of 60 mm Hg and oxygen saturation of 92% without oxygen therapy). He was discharged on GCV to outpatient follow-up on day +821, with no respiratory complaints, and improvement of the pulmonary infiltrate. CMV antigenemia test was negative a few days later.
Recent reports have suggested that prolonged GCV prophylaxis favors the occurrence of late CMVP. 4 Continuous utilization of GCV at engraftment, as prophylaxis for CMV disease, may result in a higher incidence of late CMVP, when compared to patients receiving this drug intermittently (13.4% vs 6.1%, respectively). 5 Nguyen et al 3 reported a 5% incidence of late CMVP, and the latest case was diagnosed 365 days after BMT. All patients received GCV or foscarnet until day +100 as prophylaxis for CMV, 3 so it is possible that prolonged GCV prophylaxis inhibits the development of CMV-specific T cell lymphocyte responses, promoting the occurrence of late CMVP. 5 Direct immunostaining and polymerase chain reaction (PCR) of alveolar cells obtained by BAL are important tools in the diagnosis of CMV pneumonitis. When both are positive, the predictive value for CMV pneumonitis is almost 100%. If alveolar cell immunostaining is negative, it is extremely improbable that the patient has CMV pneumonitis. However, efficacy of the procedure is based on adequate numbers of cells being collected (Ͻ5 × 10 4 cells/slide) 6 which may explain the discrepancy between BAL and viremia results in this patient.
Profound immunodeficiency, as observed in our patient and commonly seen with chronic GVHD or T cell-depleted marrow transplants, has been associated with late CMVP and a high mortality rate, ranging from 67% to 100%. 3 Patients requiring mechanical ventilation never survive. Despite his poor immune recovery, our patient had a good response to treatment and survived.
The MD Anderson group advised a probable underreporting of late CMVP. Late transplant patients often return home and adequate monitoring is no longer carried out. Thus, since more prolonged surveillance for CMV disease in high-risk patients is sometimes unavailable, long-term prophylaxis may be appropriate. Suppression of viral replication (with GCV, foscarnet or both), 7 prolonged (18 weeks) pre-emptive GCV therapy 8 or an immunologic strategy (restoration of CMV-specific T cell immunity through adoptive transfer of CMV-specific T cell clones) 9 are viable options.
In summary, as far as we know, this case illustrates the latest CMVP, that we have termed 'very late CMVP' (Ͼ1 year post transplant), reported in a BMT patient. Thus, clinicians should be alert to include CMV as a cause of interstitial pneumonia in high-risk patients, even long-term (Ͼ1 year) post BMT.
